Lukas Plachy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lukas Plachy has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Zdenek Sumnik
Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czechia
5 shared publications - Barbora Obermannova
Department of Paediatrics, 2nd Faculty of Medicine, Charles University, Prague, Czechia
4 shared publications Jan Lebl
Department of Pediatrics, Motol and Homolka University Hospital , Prague 15000
4 shared publications- Petra Dusatkova
Department of Pediatrics, 2nd Faculty of Medicine, Charles University
4 shared publications - Stanislava Kolouskova
Department of Paediatrics, 2nd Faculty of Medicine, Charles University, Prague, Czechia
4 shared publications Barbora Obermannova
Department of Pediatrics, Motol and Homolka University Hospital , Prague 15000
3 shared publications
Latest Publications
- Open Access
- 6 May 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (6)
Beyond GH stimulation tests: genetic heterogeneity and treatment response in children with diagnosed GH deficiency
Context: Growth hormone (GH) stimulation tests have limited reliability and may lead to false-positive results. Objective: This work aimed to evaluate genetic causes of short stature in children clinically diagnosed with GH deficiency (GHD) and assess genotype-phenotype correlations. Methods: A retrospective single-center study was conducted including 233 children with clinically diagnosed primary GHD treated with GH for 5 years or more. Genetic testing was performed using a targeted next-generation sequencing panel of 398 growth-associated genes. Results: A genetic cause was identified in 39 of 233 (17%) children. Only 13 of 39 (33%) findings confirmed GHD (genes CHD7, GH1, GHSR, GLI2, GNAO1, KMT2D, OTX2 [3], POU1F1, PROP1, SALL4, TBX3). The remaining 26 of 39 (67%) revealed alternative etiologies of growth failure: RASopathies (13/39; genes NF1 [2], PTPN11 [7], RAF1, SOS1 [2], SPRED1), growth plate disorders (8/39; genes ACAN, COL2A1, EXT2, FGFR3 [2], NPR2 [3]), and miscellaneous conditions (5/39; genes CDC42, LMNA, HMGA2, PMM2, RAI1). Genetically confirmed GHD patients presented with lower peak GH (median 1.8 vs 4.8 [alternative genetic etiology] and 5.9 μg/L [no genetic etiology]; P = .017), more frequent combined pituitary hormone deficiency (46% vs 4% and 12%; P = .001) and magnetic resonance imaging midbrain abnormalities (73% vs 14% vs 32%; P = .003). Conversely, the alternative etiology group demonstrated the least robust 5-year GH therapy response (median height gain 1.4 vs 2.3 [GHD group] and 1.8 [no genetic etiology]; P = .001). Conclusion: The population of children clinically diagnosed with GHD is genetically heterogeneous. A statistically significant proportion harbors defects in RAS-MAPK signaling or growth plate disorders, highlighting the limitations of current methods of GHD diagnostics.
- 6 May 2026
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (6)
Open AccessBeyond GH stimulation tests: genetic heterogeneity and treatment response in children with diagnosed GH deficiency
Context: Growth hormone (GH) stimulation tests have limited reliability and may lead to false-positive results. Objective: This work aimed to evaluate genetic causes of short stature in children clinically diagnosed with GH deficiency (GHD) and assess genotype-phenotype correlations. Methods: A retrospective single-center study was conducted including 233 children with clinically diagnosed primary GHD treated with GH for 5 years or more. Genetic testing was performed using a targeted next-generation sequencing panel of 398 growth-associated genes. Results: A genetic cause was identified in 39 of 233 (17%) children. Only 13 of 39 (33%) findings confirmed GHD (genes CHD7, GH1, GHSR, GLI2, GNAO1, KMT2D, OTX2 [3], POU1F1, PROP1, SALL4, TBX3). The remaining 26 of 39 (67%) revealed alternative etiologies of growth failure: RASopathies (13/39; genes NF1 [2], PTPN11 [7], RAF1, SOS1 [2], SPRED1), growth plate disorders (8/39; genes ACAN, COL2A1, EXT2, FGFR3 [2], NPR2 [3]), and miscellaneous conditions (5/39; genes CDC42, LMNA, HMGA2, PMM2, RAI1). Genetically confirmed GHD patients presented with lower peak GH (median 1.8 vs 4.8 [alternative genetic etiology] and 5.9 μg/L [no genetic etiology]; P = .017), more frequent combined pituitary hormone deficiency (46% vs 4% and 12%; P = .001) and magnetic resonance imaging midbrain abnormalities (73% vs 14% vs 32%; P = .003). Conversely, the alternative etiology group demonstrated the least robust 5-year GH therapy response (median height gain 1.4 vs 2.3 [GHD group] and 1.8 [no genetic etiology]; P = .001). Conclusion: The population of children clinically diagnosed with GHD is genetically heterogeneous. A statistically significant proportion harbors defects in RAS-MAPK signaling or growth plate disorders, highlighting the limitations of current methods of GHD diagnostics.
- Open Access
- 24 January 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (2) , 102
Noonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort
The variety of genes associated with Noonan syndrome spectrum disorders (NSSD) is expanding, and real-life experience with its management is increasing; however, phenotypic differences among genotypes remain poorly defined. We aimed to assess clinical characteristics and response to growth hormone (GH) therapy in a genetically confirmed, single-country multicentre NSSD cohort. We included 101 patients with NSSD (56 males) from six centres: 76 with (likely) pathogenic PTPN11 variants, 7 with SOS1 variants, and 18 with other gene variations. All completed at least one year of GH therapy; 23 reached final height. Parental heights were below average (fathers: − 0.33 SDS [− 1.19; 0.39], p < 0.01; mothers: − 0.68 SDS [− 1.47; 0.12], p < 0.001; medians [IQR]). SOS1-NS patients were born earlier (gestational week 36 [31; 37]) compared to PTPN11 -NS. Birth length (− 1.23 SDS [− 1.74; − 0.57]) was more reduced than weight (− 0.29 SDS [− 1.10; 0.54]; p < 0.0001); PTPN11- NS /SOS1 -NS had the lowest birth weights ( p < 0.05). GH was started at 6.4 years (3.8; 9.5), with baseline height-SDS − 2.92 (− 3.64; − 2.47). Median annual height-SDS increments were similar across genotypes: 0.61 (year 1; n = 101), 0.28 (year 2; n = 92), 0.21 (year 3; n = 77), 0.07 (year 4; n = 63), and 0.09 (year 5; n = 41), leading to height-SDS − 1.97 (− 2.81; − 1.42) after 5 years. Menarche occurred at age 15.7 (13.8; 17.2) years ( n = 13), and final height-SDS (available in 23 patients) reached − 1.68 (− 2.65; − 0.41). Conclusions Growth restriction in NSSD begins prenatally, especially in PTPN11-NS and SOS1-NS. GH therapy was associated with improved height SDS, with the largest height gains observed before puberty. Earlier treatment initiation may therefore be beneficial for growth outcomes. What is Known: • Noonan syndrome spectrum disorders (NSSD) are genetically heterogeneous, with pathogenic variants in the PTPN11 and SOS1 genes being most prevalent. Phenotypic differences among genotypes remain poorly defined. • Short stature is a key NSSD feature. Growth hormone (GH) therapy is beneficial, but prior studies lacked genetic justification or had limited sample sizes. What is New: • We analysed perinatal data and real-life GH outcomes in 101 genetically confirmed NSSD cases. • SOS1-NS was linked to prematurity. Birth length was more reduced than weight across genotypes; PTPN11/SOS1 cases had the lowest birth weights. GH therapy was associated with an increase in height SDS from − 2.92 to − 1.97 (median) following 5 years, and to − 1.68 in those with final height.
- 24 January 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (2) , 102
Open AccessNoonan syndrome spectrum disorders in real life: patient characteristics and response to growth hormone therapy in a genetically defined single-country multicenter cohort
The variety of genes associated with Noonan syndrome spectrum disorders (NSSD) is expanding, and real-life experience with its management is increasing; however, phenotypic differences among genotypes remain poorly defined. We aimed to assess clinical characteristics and response to growth hormone (GH) therapy in a genetically confirmed, single-country multicentre NSSD cohort. We included 101 patients with NSSD (56 males) from six centres: 76 with (likely) pathogenic PTPN11 variants, 7 with SOS1 variants, and 18 with other gene variations. All completed at least one year of GH therapy; 23 reached final height. Parental heights were below average (fathers: − 0.33 SDS [− 1.19; 0.39], p < 0.01; mothers: − 0.68 SDS [− 1.47; 0.12], p < 0.001; medians [IQR]). SOS1-NS patients were born earlier (gestational week 36 [31; 37]) compared to PTPN11 -NS. Birth length (− 1.23 SDS [− 1.74; − 0.57]) was more reduced than weight (− 0.29 SDS [− 1.10; 0.54]; p < 0.0001); PTPN11- NS /SOS1 -NS had the lowest birth weights ( p < 0.05). GH was started at 6.4 years (3.8; 9.5), with baseline height-SDS − 2.92 (− 3.64; − 2.47). Median annual height-SDS increments were similar across genotypes: 0.61 (year 1; n = 101), 0.28 (year 2; n = 92), 0.21 (year 3; n = 77), 0.07 (year 4; n = 63), and 0.09 (year 5; n = 41), leading to height-SDS − 1.97 (− 2.81; − 1.42) after 5 years. Menarche occurred at age 15.7 (13.8; 17.2) years ( n = 13), and final height-SDS (available in 23 patients) reached − 1.68 (− 2.65; − 0.41). Conclusions Growth restriction in NSSD begins prenatally, especially in PTPN11-NS and SOS1-NS. GH therapy was associated with improved height SDS, with the largest height gains observed before puberty. Earlier treatment initiation may therefore be beneficial for growth outcomes. What is Known: • Noonan syndrome spectrum disorders (NSSD) are genetically heterogeneous, with pathogenic variants in the PTPN11 and SOS1 genes being most prevalent. Phenotypic differences among genotypes remain poorly defined. • Short stature is a key NSSD feature. Growth hormone (GH) therapy is beneficial, but prior studies lacked genetic justification or had limited sample sizes. What is New: • We analysed perinatal data and real-life GH outcomes in 101 genetically confirmed NSSD cases. • SOS1-NS was linked to prematurity. Birth length was more reduced than weight across genotypes; PTPN11/SOS1 cases had the lowest birth weights. GH therapy was associated with an increase in height SDS from − 2.92 to − 1.97 (median) following 5 years, and to − 1.68 in those with final height.
- Open Access
- 17 June 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (7) , 1-9
Cytogenetic anomalies are the predominant genetic alteration in children with nonfamilial tall stature: a comparative study with familial cases
The purpose of this study is to elucidate the genetic causes and phenotypic presentation of nonfamilial tall stature (nFTS) and to compare these findings with those of familial tall stature (FTS) from the same population that was previously studied. Children with nFTS (defined as a height > + 2 SDs with both parents’ heights < + 2 SDs) underwent endocrine and anthropometric examinations and genetic testing (karyotyping, SHOX gene dosage analysis and next-generation sequencing of 786 growth-associated genes). Exome sequencing was performed in patients with negative genetic results and a height > + 3 SDs. A total of 55 children with nFTS were enrolled. The median height was + 2.8 SD (2.4–3.2 SD), and the median midparental height was + 0.7 SD (0.4–0.9 SD). Genetic causes of tall stature were identified in 6/55 (11%) children. Specifically, four children had gonosomal aneuploidy (47,XXY [2x], 47,XXX, 48,XXXX), one had a heterozygous complex rearrangement including SHOX gene duplication, and one carried a pathogenic variant in the TGFBR2 gene leading to Loeys–Dietz syndrome. A genetic cause of tall stature was significantly less common in nFTS (11%) than in our previously published cohort with FTS (32%). Conclusion: Cytogenetic abnormalities were the predominant genetic alteration identified in children with nFTS, confirming the justification of karyotype analysis in this cohort. The probability of genetic alterations was greater in children with FTS than in those with nFTS. Our findings suggest that the current guidelines for complex investigation are efficient for children with nFTS but need revision in children with FTS. What is known – what is new• Although tall stature is generally considered beneficial, it can be associated with health risks which need to be recognized in time. Tall stature without intellectual impairment is usually considered to be polygenic.• However, the cause of familial tall stature was monogenic more often than it was thought previously.• Children with non-familial and apparently non-syndromic tall stature have never been systematically investigated.• Monogenic causes of non-familial tall stature were observed in 11% of patients, including a participant with Loeys–Dietz syndrome.
- 17 June 2025
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 184 (7) , 1-9
Open AccessCytogenetic anomalies are the predominant genetic alteration in children with nonfamilial tall stature: a comparative study with familial cases
The purpose of this study is to elucidate the genetic causes and phenotypic presentation of nonfamilial tall stature (nFTS) and to compare these findings with those of familial tall stature (FTS) from the same population that was previously studied. Children with nFTS (defined as a height > + 2 SDs with both parents’ heights < + 2 SDs) underwent endocrine and anthropometric examinations and genetic testing (karyotyping, SHOX gene dosage analysis and next-generation sequencing of 786 growth-associated genes). Exome sequencing was performed in patients with negative genetic results and a height > + 3 SDs. A total of 55 children with nFTS were enrolled. The median height was + 2.8 SD (2.4–3.2 SD), and the median midparental height was + 0.7 SD (0.4–0.9 SD). Genetic causes of tall stature were identified in 6/55 (11%) children. Specifically, four children had gonosomal aneuploidy (47,XXY [2x], 47,XXX, 48,XXXX), one had a heterozygous complex rearrangement including SHOX gene duplication, and one carried a pathogenic variant in the TGFBR2 gene leading to Loeys–Dietz syndrome. A genetic cause of tall stature was significantly less common in nFTS (11%) than in our previously published cohort with FTS (32%). Conclusion: Cytogenetic abnormalities were the predominant genetic alteration identified in children with nFTS, confirming the justification of karyotype analysis in this cohort. The probability of genetic alterations was greater in children with FTS than in those with nFTS. Our findings suggest that the current guidelines for complex investigation are efficient for children with nFTS but need revision in children with FTS. What is known – what is new• Although tall stature is generally considered beneficial, it can be associated with health risks which need to be recognized in time. Tall stature without intellectual impairment is usually considered to be polygenic.• However, the cause of familial tall stature was monogenic more often than it was thought previously.• Children with non-familial and apparently non-syndromic tall stature have never been systematically investigated.• Monogenic causes of non-familial tall stature were observed in 11% of patients, including a participant with Loeys–Dietz syndrome.
- Open Access
- 31 January 2024
- Published by Galen, spol. s r.o. in Ceskoslovenska Pediatrie
- Vol. 78 (Suppl.3) , 5-10
Current view on the diagnostics of growth hormone deficiency in childhood and adolescence
Neporu?en? produkce, sekrece a funkce r?stov?ho hormonu (GH) je z?sadn? pro fyziologick? r?st ?lov?ka. Spr?vn? diagnostika deficitu r?stov?ho hormonu (GHD) je nezbytn? k v?asn?mu zah?jen? substitu?n?ho pod?v?n? GH s c?lem zlep?it t?lesnou v??k... Neporu?en? produkce, sekrece a funkce r?stov?ho hormonu (GH) je z?sadn? pro fyziologick? r?st ?lov?ka. Spr?vn? diagnostika deficitu r?stov?ho hormonu (GHD) je nezbytn? k v?asn?mu zah?jen? substitu?n?ho pod?v?n? GH s c?lem zlep?it t?lesnou v??k...
- 31 January 2024
- Published by Galen, spol. s r.o. in Ceskoslovenska Pediatrie
- Vol. 78 (Suppl.3) , 5-10
Open AccessCurrent view on the diagnostics of growth hormone deficiency in childhood and adolescence
Neporu?en? produkce, sekrece a funkce r?stov?ho hormonu (GH) je z?sadn? pro fyziologick? r?st ?lov?ka. Spr?vn? diagnostika deficitu r?stov?ho hormonu (GHD) je nezbytn? k v?asn?mu zah?jen? substitu?n?ho pod?v?n? GH s c?lem zlep?it t?lesnou v??k... Neporu?en? produkce, sekrece a funkce r?stov?ho hormonu (GH) je z?sadn? pro fyziologick? r?st ?lov?ka. Spr?vn? diagnostika deficitu r?stov?ho hormonu (GHD) je nezbytn? k v?asn?mu zah?jen? substitu?n?ho pod?v?n? GH s c?lem zlep?it t?lesnou v??k...
- Open Access
- 10 August 2023
- Published by Bioscientifica in Endocrine Connections
- Vol. 12 (10)
Analysis of children with familial short stature: who should be indicated for genetic testing?
Familial short stature (FSS) describes vertically transmitted growth disorders. Traditionally, polygenic inheritance is presumed, but monogenic inheritance seems to occur more frequently than expected. Clinical predictors of monogenic FSS have not been elucidated. The aim of the study was to identify the monogenic etiology and its clinical predictors in FSS children. Of 747 patients treated with growth hormone (GH) in our center, 95 with FSS met the inclusion criteria (pretreatment height ≤−2 SD in child and his/her shorter parent); secondary short stature and Turner/Prader–Willi syndrome were excluded criteria. Genetic etiology was known in 11/95 children before the study, remaining 84 were examined by next-generation sequencing. The results were evaluated by American College of Medical Genetics and Genomics (ACMG) guidelines. Nonparametric tests evaluated differences between monogenic and non-monogenic FSS, an ROC curve estimated quantitative cutoffs for the predictors. Monogenic FSS was confirmed in 36/95 (38%) children. Of these, 29 (81%) carried a causative genetic variant affecting the growth plate, 4 (11%) a variant affecting GH–insulin-like growth factor 1 (IGF1) axis and 3 (8%) a variant in miscellaneous genes. Lower shorter parent’s height (P = 0.015) and less delayed bone age (BA) before GH treatment (P = 0.026) predicted monogenic FSS. In children with BA delayed less than 0.4 years and with shorter parent’s heights ≤−2.4 SD, monogenic FSS was revealed in 13/16 (81%) cases. To conclude, in FSS children treated with GH, a monogenic etiology is frequent, and gene variants affecting the growth plate are the most common. Shorter parent’s height and BA are clinical predictors of monogenic FSS.
- 10 August 2023
- Published by Bioscientifica in Endocrine Connections
- Vol. 12 (10)
Open AccessAnalysis of children with familial short stature: who should be indicated for genetic testing?
Familial short stature (FSS) describes vertically transmitted growth disorders. Traditionally, polygenic inheritance is presumed, but monogenic inheritance seems to occur more frequently than expected. Clinical predictors of monogenic FSS have not been elucidated. The aim of the study was to identify the monogenic etiology and its clinical predictors in FSS children. Of 747 patients treated with growth hormone (GH) in our center, 95 with FSS met the inclusion criteria (pretreatment height ≤−2 SD in child and his/her shorter parent); secondary short stature and Turner/Prader–Willi syndrome were excluded criteria. Genetic etiology was known in 11/95 children before the study, remaining 84 were examined by next-generation sequencing. The results were evaluated by American College of Medical Genetics and Genomics (ACMG) guidelines. Nonparametric tests evaluated differences between monogenic and non-monogenic FSS, an ROC curve estimated quantitative cutoffs for the predictors. Monogenic FSS was confirmed in 36/95 (38%) children. Of these, 29 (81%) carried a causative genetic variant affecting the growth plate, 4 (11%) a variant affecting GH–insulin-like growth factor 1 (IGF1) axis and 3 (8%) a variant in miscellaneous genes. Lower shorter parent’s height (P = 0.015) and less delayed bone age (BA) before GH treatment (P = 0.026) predicted monogenic FSS. In children with BA delayed less than 0.4 years and with shorter parent’s heights ≤−2.4 SD, monogenic FSS was revealed in 13/16 (81%) cases. To conclude, in FSS children treated with GH, a monogenic etiology is frequent, and gene variants affecting the growth plate are the most common. Shorter parent’s height and BA are clinical predictors of monogenic FSS.
- Open Access
- 13 January 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1102968
Isolated growth hormone deficiency in children with vertically transmitted short stature: What do the genes tell us?
Introduction: The growth hormone deficiency (GHD) diagnosis is controversial especially due to low specificity of growth hormone (GH) stimulation tests. It is therefore believed that children diagnosed with GHD form a heterogeneous group with growth disorder frequently independent on GH function. No study evaluating the complex etiology of growth failure in children with diagnosed GHD has been performed thus far.Aims: To discover genetic etiology of short stature in children with diagnosed GHD from families with short stature.Methods: Fifty-two children diagnosed with primary GHD and vertically transmitted short stature (height SDS in the child and his/her shorter parent <-2 SD) were included to our study. The GHD diagnosis was based on growth data suggestive of GHD, absence of substantial disproportionality (sitting height to total height ratio <-2 SD or >+2 SD), IGF-1 levels GHSR and OTX2). Interestingly, in 10 (67%) children we discovered a primary growth plate disorder (ACAN, COL1A2, COL11A1, COL2A1, EXT2, FGFR3, NF1, NPR2, PTPN11 [2x]), in one (7%) a genetic variant impairing IGF-1 action (IGFALS) and in two (12%) a variant in miscellaneous genes (SALL4, MBTPS2).Conclusions: In children with vertically transmitted short stature, genetic results frequently did not correspond with the clinical diagnosis of GH deficiency. These results underline the doubtful reliability of methods standardly used to diagnose GH deficiency.
- 13 January 2023
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 1102968
Open AccessIsolated growth hormone deficiency in children with vertically transmitted short stature: What do the genes tell us?
Introduction: The growth hormone deficiency (GHD) diagnosis is controversial especially due to low specificity of growth hormone (GH) stimulation tests. It is therefore believed that children diagnosed with GHD form a heterogeneous group with growth disorder frequently independent on GH function. No study evaluating the complex etiology of growth failure in children with diagnosed GHD has been performed thus far.Aims: To discover genetic etiology of short stature in children with diagnosed GHD from families with short stature.Methods: Fifty-two children diagnosed with primary GHD and vertically transmitted short stature (height SDS in the child and his/her shorter parent <-2 SD) were included to our study. The GHD diagnosis was based on growth data suggestive of GHD, absence of substantial disproportionality (sitting height to total height ratio <-2 SD or >+2 SD), IGF-1 levels GHSR and OTX2). Interestingly, in 10 (67%) children we discovered a primary growth plate disorder (ACAN, COL1A2, COL11A1, COL2A1, EXT2, FGFR3, NF1, NPR2, PTPN11 [2x]), in one (7%) a genetic variant impairing IGF-1 action (IGFALS) and in two (12%) a variant in miscellaneous genes (SALL4, MBTPS2).Conclusions: In children with vertically transmitted short stature, genetic results frequently did not correspond with the clinical diagnosis of GH deficiency. These results underline the doubtful reliability of methods standardly used to diagnose GH deficiency.
- Open Access
Low-Carbohydrate Diet among Children with Type 1 Diabetes: A Multi-Center Study
Aims/hypothesis: The proportion of children with type 1 diabetes (T1D) who have experience with low-carbohydrate diet (LCD) is unknown. Our goal was to map the frequency of LCD among children with T1D and to describe their clinical and laboratory data. Methods: Caregivers of 1040 children with T1D from three centers were addressed with a structured questionnaire regarding the children’s carbohydrate intake and experience with LCD (daily energy intake from carbohydrates below 26% of age-recommended values). The subjects currently on LCD were compared to a group of non-LCD respondents matched to age, T1D duration, sex, type and center of treatment. Results: A total of 624/1040 (60%) of the subjects completed the survey. A total of 242/624 (39%) subjects reported experience with voluntary carbohydrate restriction with 36/624 (5.8%) subjects currently following the LCD. The LCD group had similar HbA1c (45 vs. 49.5, p = 0.11), lower average glycemia (7.0 vs. 7.9, p = 0.02), higher time in range (74 vs. 67%, p = 0.02), lower time in hyperglycemia >10 mmol/L (17 vs. 20%, p = 0.04), tendency to more time in hypoglycemia p = 0.05) and lower systolic blood pressure percentile (43 vs. 74, p = 0.03). The groups did not differ in their lipid profile nor in current body height, weight or BMI. The LCD was mostly initiated by the parents or the subjects themselves and only 39% of the families consulted their decision with the diabetologist. Conclusions/interpretation: Low carbohydrate diet is not scarce in children with T1D and is associated with modestly better disease control. At the same time, caution should be applied as it showed a tendency toward more frequent hypoglycemia.
Open AccessLow-Carbohydrate Diet among Children with Type 1 Diabetes: A Multi-Center Study
Aims/hypothesis: The proportion of children with type 1 diabetes (T1D) who have experience with low-carbohydrate diet (LCD) is unknown. Our goal was to map the frequency of LCD among children with T1D and to describe their clinical and laboratory data. Methods: Caregivers of 1040 children with T1D from three centers were addressed with a structured questionnaire regarding the children’s carbohydrate intake and experience with LCD (daily energy intake from carbohydrates below 26% of age-recommended values). The subjects currently on LCD were compared to a group of non-LCD respondents matched to age, T1D duration, sex, type and center of treatment. Results: A total of 624/1040 (60%) of the subjects completed the survey. A total of 242/624 (39%) subjects reported experience with voluntary carbohydrate restriction with 36/624 (5.8%) subjects currently following the LCD. The LCD group had similar HbA1c (45 vs. 49.5, p = 0.11), lower average glycemia (7.0 vs. 7.9, p = 0.02), higher time in range (74 vs. 67%, p = 0.02), lower time in hyperglycemia >10 mmol/L (17 vs. 20%, p = 0.04), tendency to more time in hypoglycemia p = 0.05) and lower systolic blood pressure percentile (43 vs. 74, p = 0.03). The groups did not differ in their lipid profile nor in current body height, weight or BMI. The LCD was mostly initiated by the parents or the subjects themselves and only 39% of the families consulted their decision with the diabetologist. Conclusions/interpretation: Low carbohydrate diet is not scarce in children with T1D and is associated with modestly better disease control. At the same time, caution should be applied as it showed a tendency toward more frequent hypoglycemia.
- Open Access
- 10 September 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (1) , e445-e446
Response to Letter to the Editor from Youn Hee Jee: “Familial Short Stature - A Novel Phenotype of Growth Plate Collagenopathies”
Lukas Plachy, Petra Dusatkova, Lenka Elblova, Lenka Petruzelkova, Zdenek Sumnik, Jan Lebl, Stepanka Pruhova; Response to Letter to the Editor from Youn Hee Jee:
- 10 September 2021
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (1) , e445-e446
Open AccessResponse to Letter to the Editor from Youn Hee Jee: “Familial Short Stature - A Novel Phenotype of Growth Plate Collagenopathies”
Lukas Plachy, Petra Dusatkova, Lenka Elblova, Lenka Petruzelkova, Zdenek Sumnik, Jan Lebl, Stepanka Pruhova; Response to Letter to the Editor from Youn Hee Jee: